How Can I Beat the S&P 500? What the Evidence Says
The honest answer to the most asked question in investing: how many people beat the index, why it is so hard, why investors trail even their own funds, and how daily market context fits in.
Belite Bio, Inc, healthcare (market value $6.6 billion): how it compared with the S&P 500, how it behaved in every crash since 2008, its risk‑adjusted returns and what analysts said. Returns to Oct 30, 2026; analyst data as of Nov 16, 2026.
What do the best‑ranked analysts on BLTE say now? See it in Exent Gems →
Over the 3 years to Oct 30, 2026, Belite Bio, Inc (BLTE) returned +312.5% including dividends, versus +87.4% for the S&P 500 (SPY). It beat the index by 225.1 percentage points, or +60.4% a year against +23.3%.
| Period | BLTE | S&P 500 | BLTE per year | S&P 500 per year | Result |
|---|---|---|---|---|---|
| 1 year | +46.1% | +12.0% | +46.1% | +12.0% | Beat |
| 3 years | +312.5% | +87.4% | +60.4% | +23.3% | Beat |
| Period | 1 year | 3 years |
|---|---|---|
| BLTE | +46.1% | +312.5% |
| S&P 500 | +12.0% | +87.4% |
| BLTE per year | +46.1% | +60.4% |
| S&P 500 per year | +12.0% | +23.3% |
| Result | Beat | Beat |
Total return with dividends reinvested, from month-end prices to Oct 30, 2026. Beating the index on raw return is only half the story: the next section adjusts for the risk taken. See also how to beat the S&P 500.
In the 12 months to 30 days ago, 8 analysts published 91 ratings on BLTE. Their latest calls were 100% Buy, 0% Hold and 0% Sell. 2 of them rank 4★ or higher in Exent’s analyst scoring, which is based on each analyst’s past price‑target hit rate and returns.
The consensus 12‑month price target was $245.17 (range $206.00–$303.00), +56.9% from the last price. Remember that the average analyst’s target is hit only about half the time: how accurate are price targets?
| Top‑ranked analyst covering | Firm | Stars | Price‑target hit rate |
|---|---|---|---|
| Graig Suvannavejh | Mizuho Securities | 4.8★ | 39.3% |
| Whitney Ijem | Canaccord Genuity | 4.5★ | 24.0% |
Ratings are shown with a 30‑day delay. Who the top‑ranked analysts on BLTE are, their live calls and the median target of only the top‑rated analysts are in Exent Gems.
The average analyst’s target is reached about 53.0% of the time; Exent Gems is built on the top 50 of Exent’s ranking,where some reached 90% or more over the last two years. Unlock the top 50 analysts.
BLTE beat the S&P 500 in 3 of the 3 full calendar years shown.
| Year | BLTE | S&P 500 | Difference |
|---|---|---|---|
| 2026 (to Oct 30, 2026) | −3.3% | +11.7% | −15.0% |
| 2025 | +153.5% | +17.7% | +135.8% |
| 2024 | +37.9% | +24.9% | +13.0% |
| 2023 | +51.8% | +26.2% | +25.6% |
Over 3 years, BLTE had a Sharpe ratio of 1.11 against 1.43 for the S&P 500, so it earned less return per unit of risk than the index. Its annualized volatility was 48.6% and its beta −0.27: it tended to move about −0.3× as much as the market.
| Metric | BLTE | S&P 500 |
|---|---|---|
| Annual return | +60.4% | +23.3% |
| Volatility (annualized) | 48.6% | 12.3% |
| Sharpe ratio | 1.11 | 1.43 |
| Sortino ratio | 2.75 | 3.02 |
| Max drawdown (month-end) | −24.2% | −7.6% |
| Beta to the S&P 500 | −0.27 | 1.00 |
BLTE’s deepest fall in the crises below was −22.1% in the 2025 tariff selloff, against −19.0% for the S&P 500. The last column turns that into money: what a $100,000 position would have lost from peak to trough.
| Crisis | BLTE | S&P 500 | Loss on $100,000 |
|---|---|---|---|
| 2025 tariff selloff | −22.1% | −19.0% | −$22,150 |
| Window | BLTE max drawdown |
|---|---|
| Last 1 year | −29.1% |
| Last 3 years | −36.6% |
| Last 5 years | −74.6% |
| Last 10 years | −74.6% |
Peak‑to‑trough declines from daily prices inside each crisis window. A crash replay does not predict the next crisis; it shows how much room a holding needs. Run the same replay on a whole portfolio with the crash test.
Correlation runs from −1 (moves opposite) to +1 (moves in lockstep). Over the last 36 months of monthly returns, BLTE’s correlation with the S&P 500 was −0.07, with the Nasdaq‑100 −0.04, with long Treasuries (TLT) −0.04 and with gold (GLD) 0.25.
| Least correlated large caps | Correlation | Most correlated large caps | Correlation |
|---|---|---|---|
| MPC | −0.39 | WELL | 0.27 |
| ORCL | −0.35 | AMGN | 0.25 |
| PGR | −0.27 | GOOGL | 0.24 |
| PSX | −0.26 | JNJ | 0.23 |
| IBM | −0.26 | CAT | 0.22 |
Holdings that are highly correlated behave like one position in a selloff. See how to find hidden overlap.
| Date | Rating and target | Analyst |
|---|---|---|
| Nov 16 | Target raised Buy | Graig Suvannavejh |
| Nov 16 | Target raised Buy | Whitney Ijem |
| Oct 29 | Target cut Buy | Graig Suvannavejh |
Named analysts’ rating and price‑target changes on BLTE in the 5 weeks to Oct 20, 2026, shown 30 days after publication (the free analysts’ calls 3 days after). The top‑ranked analysts’ calls are in Exent Gems. See all of the latest analyst upgrades and downgrades.
Exent matches every holding to the index with the most similar risk. For BLTE that is MDY. Comparing a holding with an index that carries very different risk makes good results look bad and risky ones look clever. Read why the S&P 500 is the wrong benchmark for most portfolios.
| Ticker | Name | 5‑year return | Volatility (5y) |
|---|---|---|---|
| LLY | Eli Lilly and Company | +482.3% | 32.6% |
| JNJ | Johnson & Johnson | +92.9% | 16.8% |
| ABBV | AbbVie Inc. | +207.1% | 23.5% |
| ORKA | Oruka Therapeutics, Inc. | +392.7% | 65.7% |
| CHE | Chemed Corporation | +12.9% | 25.4% |
| LNTH | Lantheus Holdings, Inc. | +329.5% | 56.5% |
| AMRX | Amneal Pharmaceuticals, Inc. | +291.8% | 49.8% |
| LGND | Ligand Pharmaceuticals Incorporated | +254.5% | 44.4% |
Returns are total returns from month‑end adjusted closing prices (dividends reinvested) through Oct 30, 2026. Crisis drawdowns and trailing maximum drawdowns use daily prices. Analyst coverage counts ratings published in the last 12 months, shown with a 30‑day delay. Full method: Exent methodology.
Company data as of Oct 20, 2026. The move around an earnings report runs from the close before it to the close after it; a price target counts as hit when the stock closed at or beyond it within 12 months (Exent analyst data). Revenue by region and segment, share counts and executive pay come from company filings; insider trades from SEC Form 4, short interest from FINRA, institutional ownership from 13F filings, Congress trades from STOCK Act disclosures filed with the House and Senate, federal contracts from USAspending.gov. Filings from the last 30 days are shown as counts only.
Past performance does not guarantee future results. Historical figures are calculated by Exent from market data and are for education only; they are not investment advice or a recommendation to buy or sell any security.
Wall Street’s average BLTE price target is 56.9% above the latest share price. See what the best‑ranked analysts on BLTE say now in Exent Gems.
No. As of Oct 20, 2026, BLTE (Belite Bio, Inc) is not one of the 503 stocks in the S&P 500.
No. As of Oct 20, 2026, BLTE (Belite Bio, Inc) is not one of the 101 stocks in the Nasdaq-100.
Over the 3 years to Oct 30, 2026, BLTE’s Sharpe ratio was 1.11 and its Sortino ratio 2.75, versus 1.43 and 3.02 for the S&P 500.
Among large US stocks, the lowest correlations with BLTE over the last 36 months were MPC (−0.39), ORCL (−0.35), PGR (−0.27). Its correlation with long Treasuries (TLT) was −0.04 and with gold (GLD) 0.25.
Exent ranks Wall Street analysts by their track record. Gems shows who the top‑ranked analysts on BLTE are, their latest calls and the stocks where several of them agree.
Educational content, not investment advice. Examples are illustrative; past performance does not guarantee future results.